The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVII.b

Opportunistic pulmonary/systemic infections

Publications

Hu T, Liu R, Li J, Cao J, Zhang L, Li J, Fan W, Zhong D, Shi X

[Cladribine for 13 cases refractory high-risk children Langerhans cell histiocytosis].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2014;35(11):985-9

Byrd JC, Peterson B, Piro L, Saven A, Vardiman JW, Larson RA, Schiffer C

A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.

Leukemia. 2003;17(2):323-7

Szelényi H, Foss HD, Kreuser ED, Knauf W, Thiel E

Fatal Mucor pneumonia after treatment with 2-chlorodeoxyadenosine for non-Hodgkin's-lymphoma.

Annals of hematology. 1996;73(3):145-7

Haberthür C, Pless M, Tichelli A, Gratwohl A, Speck B, Betticher DC

[Pneumocystis carinii pneumonia during therapy with 2-chlorodeoxyadenosine (2-CDA)].

Schweizerische medizinische Wochenschrift. 1994;124(1-2):73-8